France Adds Pfizer's Bevacizumab To Biosimilars List
Pfizer’s Zirabev biosimilar bevacizumab has been added to France’s list of similar biologics alongside reference brand Avastin by local medicines agency ANSM.
You may also be interested in...
Five pegfilgrastim biosimilars have been added to a newly-created group in France’s list of similar biologics, with Neulasta as the reference brand. At the same time, the country’s ANSM medicines agency has also added further biosimilars to the list against other already-listed biologic brands, and has also created new generic groups for three molecules in its répertoire of generic equivalents.
French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.
Avastin (bevacizumab), Humalog (insulin lispro) and Herceptin (trastuzumab) have been added to France’s list of similar biologics as reference brands for newly-created similarity groups by local medicines agency ANSM. They add a further three groups to the 11 created when ANSM introduced the list last year (Generics bulletin, 10 November 2017, page 11), taking the full list to 14 reference groups covering 45 biosimilar brands.